terican

Last verified · v1.0

Calculator · health

Warfarin Maintenance Dose Calculator

Calculate daily warfarin maintenance dose from current INR, target INR, weekly dose, and patient sensitivity factor.

FreeInstantNo signupOpen source

Inputs

Adjusted Daily Maintenance Dose

—

Explain my result

0/3 free

Get a plain-English breakdown of your result with practical next steps.

Adjusted Daily Maintenance Dose—mg/day

The formula

How the
result is
computed.

Understanding the Warfarin Maintenance Dose Calculator

Warfarin (brand name Coumadin) is a vitamin K antagonist anticoagulant prescribed to prevent and treat thromboembolic disorders including atrial fibrillation, deep vein thrombosis, pulmonary embolism, and mechanical heart valve thrombosis. Achieving the correct maintenance dose is clinically critical: a dose that is too low fails to prevent clotting events, while a dose that is too high precipitates serious bleeding complications. This warfarin dosing calculator provides clinicians and patients with a structured, formula-driven starting point for dose adjustments based on real-time INR response and patient-specific factors.

The Maintenance Dose Formula

The calculator applies a proportional adjustment algorithm rooted in established anticoagulation pharmacokinetics:

Dmaint = (TWD ÷ 7) × AF

  • Dmaint — Calculated daily maintenance dose (mg/day)
  • TWD — Total Weekly Dose currently prescribed (mg/week)
  • AF — Adjustment Factor, derived from the ratio of Target INR to Current INR multiplied by the patient-specific sensitivity factor

Dividing the total weekly dose by 7 converts it to an average daily baseline. Multiplying by the adjustment factor then scales the dose proportionally upward or downward to close the gap between the patient's measured INR and the therapeutic target range. The adjustment factor is calculated as: AF = (Target INR ÷ Current INR) × Patient Sensitivity Factor.

Key Variables Explained

Current INR

The International Normalized Ratio (INR) standardizes prothrombin time across different laboratory reagents and coagulometer systems worldwide. A value of 1.0 represents normal coagulation in a healthy adult not receiving anticoagulants. Warfarin therapy intentionally prolongs the INR to inhibit clot formation. According to University of Washington Anticoagulation Services, INR monitoring is typically performed every 1 to 4 weeks once the patient is stable, but more frequently during initiation, dose changes, or periods of intercurrent illness.

Target INR

Therapeutic INR targets vary by clinical indication. The majority of conditions — including non-valvular atrial fibrillation, deep vein thrombosis, and pulmonary embolism — require a target range of 2.0 to 3.0 (midpoint 2.5). Patients with mechanical mitral heart valves require a higher target of 2.5 to 3.5 due to the elevated thrombotic risk associated with that prosthesis type. Using an incorrect target range is among the most common sources of systematic warfarin dosing error.

Current Weekly Dose

Warfarin is commonly dispensed on a variable weekly schedule because non-integer average daily doses are achieved by alternating different tablet strengths across days of the week. Capturing the total weekly dose rather than a nominal daily dose prevents calculation errors that arise from these irregular tablet schedules, which may involve, for example, 5 mg on five days and 2.5 mg on two days (total: 30 mg/week).

Patient Sensitivity Factor

Warfarin pharmacokinetics vary substantially between individuals. Genetic polymorphisms in CYP2C9 (warfarin hepatic metabolism) and VKORC1 (target enzyme sensitivity) can produce two-fold to five-fold differences in steady-state dose requirement for the same INR target. Additional modulators include dietary vitamin K intake, concomitant medications (especially azole antifungals, amiodarone, and NSAIDs), hepatic function, and advancing age. The patient sensitivity factor term allows the algorithm to be calibrated to an individual's observed dose-response history and is refined iteratively as more INR data accumulate.

Clinical Example

Consider a 68-year-old patient with non-valvular atrial fibrillation whose most recent INR is 1.8 against a target of 2.5. The current prescribed weekly dose is 35 mg. The target-to-current INR ratio is 2.5 ÷ 1.8 ≈ 1.39. Applying a standard patient sensitivity factor of 1.0, the adjustment factor equals 1.39. The new estimated daily dose is (35 ÷ 7) × 1.39 ≈ 6.9 mg/day, corresponding to a weekly dose of roughly 48 mg. The prescribing clinician would round to the nearest achievable tablet combination and recheck the INR within 1 to 2 weeks.

Evidence Base and Clinical Limitations

Proportional dose-adjustment algorithms are supported by peer-reviewed anticoagulation research. A validated formula published via PubMed Central demonstrates that structured algorithmic warfarin adjustments improve time-in-therapeutic-range compared to empirical dose changes based on clinician intuition alone. The UCSD Anticoagulation Clinic dose-adjustment guidelines recommend algorithmic protocols for all warfarin modifications to reduce inter-practitioner variability. This calculator produces an estimate only. All warfarin dosing decisions must be reviewed and approved by a licensed healthcare provider with full knowledge of the patient's clinical status, comorbidities, and concurrent medications.

Reference

Frequently asked questions

What is the therapeutic INR range for most patients on warfarin?
For most clinical indications — including atrial fibrillation, deep vein thrombosis, and pulmonary embolism — the standard therapeutic INR target range is 2.0 to 3.0, with an optimal midpoint of 2.5. Patients with mechanical mitral heart valves require a higher target of 2.5 to 3.5. Using the correct target range is essential because the warfarin dosing calculator derives the adjustment factor directly from the ratio of target to current INR.
How long does it take for a warfarin dose change to affect the INR?
Warfarin has a half-life of 36 to 42 hours, so a dose change does not produce its full effect on the INR for approximately 3 to 5 days. Clinicians typically recheck the INR 5 to 7 days after any adjustment. During initiation of therapy, daily INR monitoring may be performed until two consecutive readings fall within the therapeutic range.
What foods and drugs interact with warfarin and change its effect?
Vitamin K-rich foods such as leafy green vegetables (kale, spinach, broccoli) directly antagonize warfarin's mechanism and lower the INR when consumed in large or variable quantities. Medications that significantly raise the INR include amiodarone, azole antifungals (fluconazole), metronidazole, and certain antibiotics. Drugs that lower the INR include rifampin, barbiturates, and carbamazepine. Consistent dietary vitamin K intake is more important than avoidance of specific foods.
How often should INR be monitored during stable warfarin therapy?
Once a patient achieves a stable INR within the therapeutic range on a consistent warfarin dose, INR monitoring intervals can be extended to every 4 weeks, per University of Washington Anticoagulation guidelines. More frequent monitoring — every 1 to 2 weeks — is required after any dose adjustment, during acute illness, after starting or stopping interacting medications, or following significant dietary changes.
What is the typical starting dose of warfarin for a new patient?
Most anticoagulation protocols initiate warfarin at 5 mg per day for the first 1 to 2 days in average-risk adults, then adjust based on the initial INR response. Elderly patients, those with low body weight, hepatic impairment, or known CYP2C9 or VKORC1 genetic variants that increase sensitivity typically start at 2.5 mg per day to reduce the risk of supratherapeutic INR and bleeding during induction.
What should a patient do if the INR is dangerously high on warfarin?
An INR above 4.0 in the absence of bleeding generally warrants holding one or two warfarin doses and rechecking the INR within 24 to 48 hours, according to UCSD Anticoagulation Clinic protocols. An INR above 10.0 or any INR associated with active bleeding requires urgent medical evaluation. Reversal agents including oral or intravenous vitamin K, four-factor prothrombin complex concentrate (4F-PCC), or fresh frozen plasma may be used depending on bleeding severity and urgency.